Drug major Cipla has acquired two US-based firms InvaGen Pharmaceuticals and Exelan Pharmaceuticals for $550 million, the company said in a regulatory filing here on Thursday.
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Drug major Cipla has acquired two US-based firms InvaGen Pharmaceuticals and Exelan Pharmaceuticals for $550 million, the company said in a regulatory filing here on Thursday.
A drug used for Type-2 diabetes may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes, new research has found.
Researchers have identified autoantibodies immune proteins found in the blood that fight one's own proteins that can potentially detect lung cancer early by distinguishing between smokers with or without lung cancer.
Pharma major Dr.Reddy's Laboratories has decided to buyback around 44,84,049 of equity shares of around 2.6 percent for Rs.1,569.4 crore as it has strong cash flows.
Offering a target for developing new therapies to address sleep disorders, researchers have identified a gene that when overactivated causes severe insomnia.
A new non-surgical, painless medical procedure which reduces fat from the body within a day or two was launched day.
Tobacco products were cheaper than essential food items in India, says a new study."The current excise and Value Added Tax (VAT) rates are insufficient to increase the prices of tobacco products, therefore making these products easily affordable," said the study conducted by the Institute for Studies in Industrial Development (ISID) and Public Health Foundation of India (PHFI).
The union cabinet on Wednesday gave its approval for an agreement to be signed between the AYUSH ministry and the World Health Organisation (WHO) for collaborative activities.
Results of a recent clinical study have shown that an anti-cancer drug that triggers cell death in various tumour types, may have clinical potential for some blood cancers including mantel cell lymphoma (MCL) and acute myeloid leukemia (AML).
Biota Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its antiviral compound, BTA585, for the treatment of respiratory syncytial virus (RSV) infections in infants, young children and adults.